Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jazz Pharmaceuticals (JAZZ) PT Lowered to $200 at Cowen
November 7, 2018 8:57 AM ESTCowen analyst Ken Cacciatore lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $200.00 (from $220.00) while maintaining a Outperform rating.
... MoreJazz Pharmaceuticals (JAZZ) PT Lowered to $203 at BMO Capital
November 7, 2018 8:56 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $203.00 (from $206.00) while maintaining a Outperform rating.
The analyst commented, "JAZZ reported mixed 3Q results with revenue of $469mm below BMO/consensus $478mm/$483mm, and adj. EPS of $3.58 ahead of... More
Jazz Pharmaceuticals (JAZZ) PT Lowered to $184 at RBC Capital
November 7, 2018 7:22 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $184.00 (from $194.00) while maintaining a Outperform rating.
... More